聚乙二醇化脂质体阿霉素联合地塞米松和硼替佐米（VMD方案）或来那度胺（RMD方案）用于多发性骨髓瘤预处理患者。 - Suppr

Suppr

超能文献

Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.

作者信息

Buda Gabriele, Orciuolo Enrico, Galimberti Sara, Pelosini Matteo, Petrini Mario

出版信息

Ann Hematol. 2011 Sep;90(9):1115-6. doi: 10.1007/s00277-010-1136-5. Epub 2010 Dec 22.

DOI:10.1007/s00277-010-1136-5

PMID:21181162

Abstract

摘要

相似文献

Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.

Ann Hematol. 2011 Sep;90(9):1115-6. doi: 10.1007/s00277-010-1136-5. Epub 2010 Dec 22.

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.

J Clin Oncol. 2010 Feb 10;28(5):800-7. doi: 10.1200/JCO.2009.22.7561. Epub 2010 Jan 4.

Treatment of multiple myeloma: 2009 update.

Prescrire Int. 2009 Dec;18(104):263-6.

A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.

Leukemia. 2012 Jul;26(7):1675-80. doi: 10.1038/leu.2012.51. Epub 2012 Feb 22.

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.

Cancer. 2008 Apr 1;112(7):1529-37. doi: 10.1002/cncr.23326.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

J Clin Oncol. 2007 Sep 1;25(25):3892-901. doi: 10.1200/JCO.2006.10.5460. Epub 2007 Aug 6.

A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients.

Br J Haematol. 2011 Dec;155(5):580-7. doi: 10.1111/j.1365-2141.2011.08884.x. Epub 2011 Sep 26.

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus doxorubicin and dexamethasone as induction therapy in previously untreated multiple myeloma patients.

Acta Haematol. 2013;129(1):35-9. doi: 10.1159/000339635. Epub 2012 Oct 26.

A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.

Ann Hematol. 2011 Feb;90(2):193-200. doi: 10.1007/s00277-010-1052-8. Epub 2010 Sep 1.

Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.

Eur J Haematol. 2007 Apr;78(4):297-302. doi: 10.1111/j.1600-0609.2007.00823.x. Epub 2007 Feb 5.

引用本文的文献

Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/β-catenin signal pathway in prostate cancer cells.

BMC Cancer. 2021 Oct 13;21(1):1101. doi: 10.1186/s12885-021-08841-1.

Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety.

Front Oncol. 2021 Mar 25;11:597453. doi: 10.3389/fonc.2021.597453. eCollection 2021.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.

作者信息

Buda Gabriele, Orciuolo Enrico, Galimberti Sara, Pelosini Matteo, Petrini Mario

出版信息

Ann Hematol. 2011 Sep;90(9):1115-6. doi: 10.1007/s00277-010-1136-5. Epub 2010 Dec 22.

DOI:10.1007/s00277-010-1136-5

PMID:21181162

Abstract

摘要